Profile data is unavailable for this security.
About the company
Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. The Del-desiran is designed to treat people with myotonic dystrophy type 1 (DM1) and is in the global Phase III HARBOR trial and in the ongoing MARINA-OLE trial in people with DM1. The Delpacibart braxlosiran is the first investigational therapy designed to directly target DUX4 in people living with facioscapulohumeral muscular dystrophy (FSHD). The Del-zota is designed for people with Duchenne muscular dystrophy (DMD) and is in development with the Phase II EXPLORE44 open-label extension (OLE) study.
- Revenue in USD (TTM)20.87m
- Net income in USD-549.79m
- Incorporated2012
- Employees391.00
- LocationAvidity Biosciences Inc3020 CALLAN ROADSAN DIEGO 92121United StatesUSA
- Phone+1 (858) 401-7900
- Fax+1 (302) 636-5454
- Websitehttps://www.aviditybiosciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PTC Therapeutics, Inc. | 1.78bn | 751.72m | 5.69bn | 939.00 | 8.31 | -- | 7.26 | 3.20 | 8.53 | 8.53 | 21.64 | -1.95 | 0.7932 | 1.28 | 8.83 | 1,894,728.00 | 33.51 | -26.68 | 49.97 | -34.84 | 96.83 | 93.49 | 42.25 | -74.67 | 2.26 | 6.03 | 1.07 | -- | -13.97 | 21.32 | 42.02 | -- | -13.92 | -- |
| Rhythm Pharmaceuticals Inc | 174.33m | -197.71m | 6.57bn | 283.00 | -- | 44.12 | -- | 37.69 | -3.10 | -3.10 | 2.74 | 4.43 | 0.4006 | 1.03 | 6.66 | 616,021.20 | -44.19 | -52.46 | -57.53 | -61.22 | 89.40 | -- | -110.32 | -354.18 | 4.53 | -27.83 | 0.2693 | -- | 68.06 | -- | -43.26 | -- | -- | -- |
| Krystal Biotech Inc | 373.16m | 198.91m | 7.91bn | 275.00 | 40.92 | 6.94 | 38.67 | 21.19 | 6.66 | 6.66 | 12.50 | 39.26 | 0.3358 | 0.7616 | 3.29 | 1,356,960.00 | 17.90 | -4.81 | 19.49 | -5.07 | 94.26 | -- | 53.30 | -41.51 | 9.73 | -- | 0.00 | -- | 473.02 | -- | 715.58 | -- | -7.91 | -- |
| Halozyme Therapeutics, Inc. | 1.24bn | 595.49m | 9.35bn | 350.00 | 16.72 | 18.54 | 13.80 | 7.52 | 4.76 | 4.76 | 9.90 | 4.29 | 0.5728 | 1.21 | 3.93 | 3,551,006.00 | 27.45 | 22.20 | 35.10 | 25.70 | 84.55 | 80.85 | 47.91 | 45.39 | 1.37 | -- | 0.7499 | 0.00 | 22.44 | 38.95 | 57.71 | -- | 21.50 | -- |
| Axsome Therapeutics Inc | 561.26m | -229.53m | 9.39bn | 683.00 | -- | 127.06 | -- | 16.73 | -4.67 | -4.67 | 11.40 | 1.47 | 0.9121 | 2.40 | 3.50 | 821,761.40 | -37.30 | -59.62 | -68.09 | -80.32 | 91.86 | -- | -40.89 | -134.06 | 1.50 | -28.27 | 0.7255 | -- | 42.53 | -- | -20.05 | -- | 75.71 | -- |
| Jazz Pharmaceuticals PLC | 4.16bn | -368.48m | 10.10bn | 2.80k | -- | 2.55 | 31.79 | 2.43 | -6.07 | -6.07 | 67.81 | 65.18 | 0.3522 | 0.936 | 5.59 | 1,484,940.00 | -3.12 | 1.36 | -3.62 | 1.50 | 88.49 | 88.18 | -8.85 | 3.98 | 1.44 | 2.17 | 0.5752 | 0.00 | 6.12 | 13.48 | 35.02 | 1.37 | -23.40 | -- |
| Avidity Biosciences Inc | 20.87m | -549.79m | 11.28bn | 391.00 | -- | 5.67 | -- | 540.72 | -4.17 | -4.17 | 0.1589 | 12.85 | 0.0111 | -- | 2.78 | 53,370.84 | -29.13 | -30.46 | -31.29 | -33.14 | -- | -- | -2,634.59 | -1,901.74 | -- | -- | 0.00 | -- | 13.99 | 36.27 | -51.87 | -- | 97.52 | -- |
| Biomarin Pharmaceutical Inc | 3.09bn | 520.42m | 11.59bn | 3.04k | 22.60 | 1.91 | 19.21 | 3.74 | 2.67 | 2.67 | 15.82 | 31.53 | 0.4278 | 0.4512 | 3.95 | 1,017,764.00 | 7.20 | 2.18 | 8.04 | 2.46 | 81.32 | 76.43 | 16.82 | 6.07 | 3.10 | -- | 0.0897 | 0.00 | 17.97 | 10.86 | 154.62 | -- | -9.83 | -- |
| Elanco Animal Health Inc | 4.59bn | 36.00m | 12.77bn | 9.00k | 358.98 | 1.89 | 18.09 | 2.78 | 0.0716 | 0.0716 | 9.23 | 13.58 | 0.3422 | 1.24 | 5.30 | 510,111.10 | 0.2683 | -2.71 | 0.2993 | -3.02 | 54.96 | 54.72 | 0.7841 | -9.52 | 1.23 | 1.30 | 0.3735 | -- | 0.4981 | 7.65 | 127.46 | 37.85 | -3.99 | -- |
| Neurocrine Biosciences Inc | 2.68bn | 428.00m | 13.70bn | 1.80k | 32.82 | 4.56 | 29.94 | 5.11 | 4.19 | 4.19 | 26.25 | 30.13 | 0.6878 | 0.7611 | 4.44 | 1,490,389.00 | 10.97 | 10.41 | 12.71 | 12.71 | 98.37 | 98.47 | 15.95 | 15.71 | 3.27 | -- | 0.00 | -- | 24.81 | 24.48 | 36.68 | 55.94 | 20.97 | -- |
| BridgeBio Pharma Inc | 353.78m | -797.12m | 14.13bn | 725.00 | -- | -- | -- | 39.94 | -4.19 | -4.19 | 1.86 | -10.03 | 0.4254 | -- | -- | 487,972.40 | -96.88 | -75.74 | -125.35 | -94.24 | 95.78 | 96.67 | -227.74 | -716.92 | 3.76 | -2.89 | 3.52 | -- | 2,285.27 | 40.48 | 16.70 | -- | 11.63 | -- |
| Moderna Inc | 2.23bn | -3.12bn | 15.83bn | 5.80k | -- | 1.70 | -- | 7.09 | -8.05 | -8.05 | 5.76 | 23.86 | 0.1598 | 2.19 | 1.71 | 384,827.60 | -22.31 | 13.72 | -25.91 | 18.76 | 63.49 | 76.34 | -139.61 | 23.74 | 3.73 | -- | 0.0061 | 0.00 | -52.75 | 121.86 | 24.46 | -- | 101.61 | -- |
Data as of Feb 11 2026. Currency figures normalised to Avidity Biosciences Inc's reporting currency: US Dollar USD
64.99%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 30 Sep 2025 | 20.11m | 14.00% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 12.53m | 8.72% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2025 | 9.65m | 6.72% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 9.41m | 6.55% |
| RA Capital Management LPas of 30 Sep 2025 | 8.64m | 6.02% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 7.91m | 5.51% |
| Janus Henderson Investors US LLCas of 28 Nov 2025 | 7.89m | 5.49% |
| Avoro Capital Advisor LLCas of 30 Sep 2025 | 7.65m | 5.32% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 4.89m | 3.40% |
| RTW Investments LPas of 29 Oct 2025 | 4.69m | 3.26% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
